Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients

NCT02437279 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Stage III Skin Melanoma

Interventions

PROCEDURE: Surgery of the tumor
DRUG: Infusion with ipilimumab 3 mg/kg q3wks
DRUG: Infusion with nivolumab 1 mg/kg q3wks

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]